No abstract

Background Ataxia telangiectasia-mutated (ATM) gene contributes to repair damaged DNA and to regulate cell cycle; therefore, ATM variants seem to increase breast cancer risk; however, the results are controversial. So we conducted a systematic review and meta-analysis to clarify the pooled association between various ATM variants and the risk of breast cancer. Methods The relevant studies were searched through Scopus, Web of Science, PubMed and Cochrane. Stratified and subgroup analyses were performed to explore heterogeneity between studies and assess effects of study quality. The pooled estimates logarithm with standard error logarithm of odds ratio and relative risk with confidence interval were calculated. Results This study revealed that there is association between ATM variants and the risk of breast cancer; according to the seven adjusted case-control studies, OR of this association was estimated as 1.67 (95%CI: 0.73–3.82), according to nine unadjusted case-control studies, the crude OR was 2.27 (95% CI: 1.17–4.40) and according to two cohorts, the RR was estimated as 1.68 (95% CI: 1.17–2.40). Conclusions The ATM variants are associated with an increased risk of breast cancer that ATM V2424G mutation is detected as the most predisposing factor while ATM D1853V, L546V, and S707P variants have the least predictive ability.

Background and Objectives: The Kerlan-Jobe Orthopedic Clinic Shoulder and Elbow Score (KJOC-SES) is a reliable and sensitive tool used to measure the performance and function in overhead athletes with shoulder and elbow injuries. This study aimed to culturally adapt and validate the KJOC-SES questionnaire in the Persian language. Materials and Methods: A total number of 341 healthy competitive overhead athletes took part in this cross-sectional study and completed the KJOC-SES questionnaire. To assess the reliability of the KJOC-SES, 41 professional volleyball players filled out the questionnaire at the baseline and after a 4-week interval, during the off-season. Also, we compared the scores of KJOC-SES with those of the sports/performing arts module of disabilities of the arm, shoulder, and hand and the 12-item short-form health survey to test the construct validity. Moreover, we investigated the internal consistency and the concurrent validity of all measures. Results: The KJOC-SES was correlated with the sports/performing arts module of the disabilities of the arm, shoulder, and hand (r=−0.559, P<0.001), and the 12-item short-form health survey (r=−0.505, P<0.001). The KJOC-SES had an excellent internal consistency (the Cronbach alpha=0.92). Also, the intra-class correlation coefficients of test-retest reliability for the 10 items of KJOC-SES were excellent (ICC=0.82, P<0.001). The new score correctly stratified overhead athletes by the injury category (P<0.001). Conclusion: The KJOC-SES is a valid and reliable tool for assessing the shoulder and elbow injuries in Iranian overhead athletes.

No abstract

Gliomas make up virtually 80% of all lethal primary brain tumors and are categorized based on their cell of origin. Glioblastoma is an astrocytic tumor that has an inferior prognosis despite the ongoing advances in treatment modalities. One of the main reasons for this shortcoming is the presence of the blood-brain barrier and blood-brain tumor barrier. Novel invasive and non-invasive drug delivery strategies for glioblastoma have been developed to overcome both the intact blood-brain barrier and leverage the disrupted nature of the blood-brain tumor barrier to target cancer cells after resection—the first treatment stage of glioblastoma. Exosomes are among non-invasive drug delivery methods and have emerged as a natural drug delivery vehicle with high biological barrier penetrability. There are various exosome isolation methods from different origins, and the intended use of the exosomes and starting materials defines the choice of isolation technique. In the present review, we have given an overview of the structure of the blood-brain barrier and its disruption in glioblastoma. This review provided a comprehensive insight into novel passive and active drug delivery techniques to overcome the blood-brain barrier, emphasizing exosomes as an excellent emerging drug, gene, and effective molecule delivery vehicle used in glioblastoma therapy. Supplementary Information The online version contains supplementary material available at 10.1007/s12035-023-03365-0.